The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Simmons & Simmons

Work +44 20 7628 2020
Fax +44 20 7628 2070

Charles Mayo

Work 020 7825 4410
Simmons & Simmons

Work Department

Corporate/corporate and commercial.


Charles advises a wide range of leading listed companies, investment banks and brokers. He specialises in public/private partnerships, equity capital markets, and mergers and acquisitions transactions. Charles regularly advises on the listing, disclosure, prospectus and transparency rules and participates in a series of workshops on these rules with the Financial Services Authority and the London Stock Exchange. Charles also specialises in advising on the legal aspects of corporate governance and compliance, including advising on the Bribery Act. He also has particular experience in the life sciences, aerospace and defence and transport sectors. Charles’s recent experience includes: advising the Ministry of Defence on the public/private partnership with Carlyle in relation to QinetiQ, including the £1.3bn IPO of QinetiQ on the Official List, the first UK Government IPO for nearly a decade; advising the selling shareholders of Specifar Pharmaceuticals S.A., a generic drug developer, on the US$562m acquisition of the company by Watson Pharmaceuticals Inc.; advising on the ‘virtual’ acquisitions and AIM IPOs of Center Parcs and of Anker and on the IPOs of Plethora (UK), Endace (NZ) and Asian Citrus (China), Sinclair Pharma on its Main Market listings in London and Paris, Japaninvest on its Tokyo listing and CLSA as sponsor of the Hong Kong listing of RCG, the first Hong Kong Stock Exchange listing of an AIM-traded company; and advising the UK Government on the Energy Technology Institute, a not-for-profit public/private partnership to research lower carbon energy to help tackle climate change. Charles and Nick Benwell (litigation partner) led the team that won the Innovation in Anti-bribery and Corruption award at the Financial Times European Innovative Lawyers Awards 2011. Charles was also behind the firm winning the 2011 Best Regulatory Law Firm of the Year Award at the Thomson Reuters Accelus 7th Annual Compliance Awards. The Legal 500 UK highlighted Charles as a ‘Leading Individual’ in the pharmaceutical and biotechnology sector.


Partner 1992; Hong Kong office 2007-09; member CBI Companies Committee and Primary Markets Group of the London Stock Exchange; recently appointed member Legal Experts Network of the Association of the British Pharmaceutical Industry.

London: Public sector


Within: Healthcare

Simmons & Simmons predominantly focuses on advising private healthcare providers and investors on mid-market private M&A, joint ventures and private equity transactions. The team, led by Jocelyn Ormond, also has a strong offering in digital health, particularly in relation to complex IT infrastructure arrangements, market access, product liability, cross-departmental collaborations and investments. Charles Mayo specialises in public/private partnerships.

[back to top]

London: TMT (technology, media and telecoms)

Pharmaceuticals and biotechnology

Within: Leading individuals

Charles Mayo - Simmons & Simmons

Within: Pharmaceuticals and biotechnology

The Simmons & Simmons healthcare and life sciences group is headed by Michael Gavey (together with Alexandre Regniault  in Paris). Its client roster ranges from major pharmaceutical and medical device and biotech companies to healthcare operators and charities such as the Institute of Cancer Research. Gavey also heads the IP team and digital health group and assists clients with IP-related transactions, regulatory regimes and compliance. Michael Burdon and Scott Parker deal with patent litigation, often involving multiple jurisdictions. Charles Mayo is a corporate partner who advises on a wide range of commercial and finance matters. Associate Lydia Torne is noted for her IP transactional and regulatory compliance work involving a range of healthcare products.

[back to top]

Back to index

Legal Developments by:
Simmons & Simmons

  • Failure to counter financial crime: Norwich Union Life

    In December 2007, the Financial Services Authority (FSA) imposed a fine of £1.26m on Norwich Union Life (part of the Aviva Group), one of the largest life insurance businesses in the UK with around seven million customers. The fine related to failures to take reasonable care to establish and maintain effective systems and controls for countering the risks of financial crime. The fine is the latest confirmation of the emphasis being placed on protecting clients and customers from the threat of financial crime.
    - Simmons & Simmons

Legal Developments in London

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to